Passions

1,000-piece puzzles

Indoor cycling

Experience

Cooley Advises on Keros’ Strategic Review Process, Negotiated Share Repurchase Transactions and Planned Issuer Tender Offer

October 15, 2025

Cooley advised Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its $375 million capital return program, which represents the culmination of Keros’ strategic review process, including its share purchase agreements to repurchase all shares of its common stock beneficially owned by ADAR1 Capital Management and Pontifax Venture Capital and planned tender offer for up to $194 million in value of shares of its common stock.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
Minkyu Park
Special Counsel, New York
Julia Kim
Special Counsel, New York
Kathryn Benvenuti
Associate, New York
Koji Fukumura
Partner, San Diego
Sarah Lightdale
Partner, New York
Craig TenBroeck
Partner, San Diego
Elizabeth Wright
Special Counsel, Boston
Margaux Arntson
Associate
Susan Choy
Associate, New York
Brian P. Golger
Associate, New York
Jill Golub
Associate, New York
Denny Xu
Associate, Boston
Jeffrey J. Tolin
Partner, New York
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, San Diego

Related Practices & Industries

Michael Horvath Closes Seed Round in FeMMA

August 14, 2025

Cooley advised Michael Horvath, co-founder and former CEO of Strava, on his lead seed round investment in FeMMA, a new app connecting women through martial arts.

Related contacts

Laura Stoffel
Partner, Boston
Margaux Arntson
Associate

Related Practices & Industries

Caris Life Sciences Announces $494 Million IPO

June 20, 2025

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

Related contacts

Eric Blanchard
Partner, Boston
Div Gupta
Partner, New York
Charlie Kim
Partner, San Diego
Minkyu Park
Special Counsel, New York
Mark Ballantyne
Partner, Reston
Ariane A. Andrade
Partner, Chicago
Shamis Beckley
Partner, Boston
Caitlin Courtney
Partner, Palo Alto
Annie Froehlich
Partner, Washington, DC
Daniel Grooms
Partner, Washington, DC
Phil Mitchell
Partner, New York
Sonia Nath
Partner, Washington, DC
Gerard O'Shea
Partner, New York
Tracy Rubin
Partner, Palo Alto
Francis Wheeler
Senior Counsel, Colorado
Son Nguyen
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
William Corcoran
Of Counsel, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Trevor Bossi
Associate, Boston
Cara Buchicchio
Associate, New York
Eric J. Delgado
Associate, New York
Matthew Iannone
Associate, New York
Wyatt Kernell
Associate, Colorado
Allison Kutner
Associate, New York
Calvin Lee
Associate, New York
Amiti C. Rothstein
Associate, New York
Dr. Jason Valentine
Associate, Washington, DC
Margaux Arntson
Associate

Related Practices & Industries

Xometry Announces $250 Million Convertible Senior Notes Offering

June 16, 2025

Cooley advised Xometry, the global artificial intelligence-powered marketplace connecting buyers with suppliers of manufacturing services, on its $250 million aggregate principal amount of 0.75% convertible senior notes due 2030, which includes the initial purchasers’ option to purchase up to an additional $25 million aggregate principal amount of notes.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Eric Blanchard
Partner, Boston
Jason Savich
Partner, San Francisco
Shimeng Cheng
Special Counsel, San Francisco
Trey Reilly
Associate, New York
Trevor Bossi
Associate, Boston
Eileen Marshall
Partner, Washington, DC
Timothy Shapiro
Partner, Palo Alto
Francis Wheeler
Senior Counsel, Colorado
Margaux Arntson
Associate
Margaret Barreto
Associate, San Francisco
Matt Kong
Associate, San Francisco

Related Practices & Industries

Tenet Medicines to Be Acquired by Eliem Therapeutics

April 11, 2024

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.

Read more

Related contacts

Elizabeth Galvin
Associate, Boston
Miguel J. Vega
Partner, Boston
Eric Blanchard
Partner, Boston
Ryan Sansom
Partner, Boston
Mike Nelson
Partner, Colorado
Kurtis Zinger
Associate, Colorado
Margaux Arntson
Associate
Stephanie Gentile
Partner, New York
Ryan Montgomery
Partner, Boston
Megan Browdie
Partner, Washington, DC
Phil Mitchell
Partner, New York
Geoffrey Spolyar
Partner, Boston
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Trevor Bossi
Associate, Boston
Wyatt Kernell
Associate, Colorado
Nicollette R. Kirby
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Steven A. Zuckerman
Associate, New York
Stacy Colter
Senior Paralegal, New York
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Admissions and credentials

Massachusetts

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.